Clinical characteristics and outcomes of lung cancer with pulmonary embolism

Oncology

Volumn 77, Issue 2, 2008, Pages 100-106

  Chuang, Yu Min ^a   Yu, Chong Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Lung cancer; Prognosis; Pulmonary embolism; Survival

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; WARFARIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; LUNG CANCER; LUNG EMBOLISM; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SURGERY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PULMONARY EMBOLISM; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67650705642     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229503     Document Type: Article

References (30)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy (review). Chest 2004; 126: 338S-400S.
2. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
3. Goldhaber SZ: Pulmonary embolism. Lancet 2004; 363: 1295-1305.
4. Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389. (Pubitemid 29192409)
5. Ribeiro A, Lindmarker P, Johnsson H, Juh-lin-Dannfelt A, Jorfeldt L: Pulmonary embolism: one-year follow-up with echocardiog-raphy Doppler and five-year survival analysis. Circulation 1999; 99: 1325-1330.
6. Kearon C: Natural history of venous throm-boembolism. Circulation 2003; 107:I22-I30.
7. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J: Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 416-420.
8. Kelly J, Hunt BJ: A clinical probability assessment and D-dimer measurement should be the initial step in the investigation of suspected venous thromboembolism. Chest 2003; 124: 1116-1119.
9. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE: Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrom-botic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
10. Wittram C, Maher MM, Yoo AJ, Kalra MK, Shepard JA, McLoud TC: CT angiography of pulmonary embolism: diagnostic criteria and causes of misdiagnosis. Radiographics 2004; 24: 1219-1238.
11. Varki A: Trousseau's syndrome: Multiple definitions and multiple mechanisms. Blood 2007; 110: 1723-1729.
12. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet On-col 2005; 6: 401-410.
13. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S: Mic-roparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5: 520-527.
14. Lee AY, Levine MN: Venous thromboembo-lism and cancer: risks and outcomes. Circulation 2003; 107:I17-I21.
15. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL: Incidence of cancer after primary deep venous thrombosis or pulmonary embolism. Lakartidningen 2000; 97: 1961-1964.
16. Tesselaar ME, Osanto S: Risk of venous thromboembolism in lung cancer (review). Curr Opin Pulm Med 2007; 13: 362-367.
17. Blom JW, Osanto S, Rosendaal FR: The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 2: 1760-1765.
18. Kuter DJ: Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004; 9: 207-216.
19. Anderson AJ, Krasnow SH, Boyer MW, Cutler DJ, Jones BD, Citron ML, Ortega LG, Cohen MH: Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 1989; 95: 71-75.
20. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, Macleod D, Burton E, An-dreou P, Anderson DR: Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23: 4063-4069.
21. Klerk CP, Smorenburg SM, Buller HR: Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med 2003; 163: 1913-1921.
22. Ger LP, Hsu WL, Chen KT, Chen CJ: Risk factors of lung cancer by histological category in Taiwan. Anticancer Res 1993; 13: 1491-1500.
23. Stein PD, Terrin ML, Hales CA, Palevsky HI, Saltzman HA, Thompson BT, Weg JG: Clin- syndrome: ical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest 1991; 100: 598-603.
24. Unsal E, Atalay F, Atikcan S, Yilmaz A: Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004; 98: 93-98.
25. Lee AY, Julian JA, Levine MN, Weitz JI, Kearon C, Wells PS, Ginsberg JS: Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med 1999; 131: 417-423.
26. Gomes MP, Deitcher SR: Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park) 2003; 17: 126-135, 139; discussion 139-144.
27. Tilyou S: PIOPED (Prospective Investigation in Pulmonary Embolism Diagnosis) study compares lung scans and pulmonary arteri-ography. J Nucl Med 1989; 30: 279-280.
28. Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA Jr, Fossieck BE Jr, Minna JD: Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981; 65: 187-195.
29. Watine J: Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand J Clin Lab Invest 2000; 60: 259-273.
30. Tas F, Aydiner A, Demir C, Topuz E: Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin On-col 2001; 24: 376-378.